Prospectus
Released
Released
Announcement PDF
cytl0001_2100021_207.docx
CYNATA THERAPEUTICS LIMITED
ACN 104 037 372
PROSPECTUS
For a non-accelerated, renounceable pro rata entitlement offer of 3 New Shares for
every 8 Shares held by Eligible Shareholders, and one free attaching Entitlement
Option for every 3 New Shares issued, at an Offer Price of $0.01 per New Share, to
raise approximately $913,000 (Entitlement Offer);
and
For an offer of 18,000,000 Underwriter Options to Caravel Securities Pty Ltd
(Underwriter Option Offer).
The last date for acceptance and payment under the Entitlement Offer will be 5.00pm (Melbourne
time) on Tuesday, 27 October 2026 (unless the Entitlement Offer is extended).
The Underwriter Option Offer is only open to the Underwriter.
The Entitlement Offer is being lead managed and fully underwritten by Caravel Securities Pty Ltd.
IMPORTANT INFORMATION
This Prospectus is important and should be read in its entirety. If after reading this Prospectus you
have any questions about the securities being offered under this Prospectus or any other matter, then
you should consult your stockbroker, accountant or other professional adviser.
The securities offered under this Prospectus should be considered as highly speculative.
THE DOCUMENT IS IMPORTANT AND SHOULD BE READ IN ITS ENTIRETY
Not for release to US wire services or distribution in the United States
P a g e | 1
cytl0001_2100021_207.docx
IMPORTANT NOTICE
Prospectus
This Prospectus relates to:
• an offer of new fully paid ordinary shares (New Shares) and attaching Entitlement Options in Cynata Therapeutics Limited
ACN 104 037 372 (ASX: CYP) (Cynata or Company) under the Entitlement Offer;
• the Underwriter Option Offer, being an offer of Underwriter Options to the Underwriter (or nominee(s)); and
• the offer of Shortfall Securities under the Entitlement Offer that are not applied for by Eligible Shareholders under this
Prospectus (Shortfall Offer). See Sections 4.4 and 5.7 for further details.
The Entitlement Offer, Underwriter Option Offer and Shortfall Offer are referred to as the Offers.
This Prospectus is dated 8 October 2026 and was lodged with the Australian Securities and Investments Commission (ASIC) on
that date. The expiry date of the Prospectus is 5.00pm (Melbourne time) on the date that is 13 months after the date of this
Prospectus (Expiry Date). No securities will be issued on the basis of this Prospectus after the Expiry Date.
Transaction-specific Prospectus
This Prospectus is a ‘transaction-specific’ prospectus to which the special content rules under section 713 of the Corporations Act
2001 (Corporations Act) apply. This allows the issue of a concise prospectus in relation to an offer of securities, or options to
acquire securities, in a class which has been continuously quoted by the Australian Securities Exchange (ASX) in the three
months prior to the date of the prospectus. This Prospectus does not include all of the information that would be disclosed for an
initial public offering of securities.
An application for quotation of the New Shares will be made to ASX within 7 days after the date of this Prospectus.
The Options will not be quoted on ASX and accordingly the Company will not apply to have the Options quoted on ASX.
ASX maintains a database of publicly available information issued by the Company as a disclosing entity.
None of ASIC, ASX or their respective officers, take any responsibility for the contents of this Prospectus or the merits of the
securities to which this Prospectus relates.
Entitlement Offer
The Offers contained in this Prospectus include an invitation to Eligible Shareholders to acquire 3 New Shares for every 8 fully
paid ordinary Cynata shares (Shares) held on the Record Date, plus one free attaching Entitlement Option for every 3 New
Shares issued to Eligible Shareholders under this Prospectus, at an offer price of $0.01 per New Share (Offer Price), to raise
approximately $913,000 (before costs) (Entitlement Offer).
Each Entitlement Option issued pursuant to this Prospectus will have an exercise price of $0.02 and will expire on the date which
is 2 years and 6 months from the date of issue of the Entitlement Options.
The Entitlement Options will not be quoted on ASX.
The Entitlement Offer is renounceable. Entitlements may be traded on ASX during the Entitlement Trading Period.
The Entitlement Offer is fully underwritten by Caravel Securities Pty Ltd: see Section 10.3 for further details.
Underwriter Option Offer
The Offers contained in this Prospectus include an offer of 18,000,000 Underwriter Options in consideration for services provided
to the Company by Caravel Securities Pty Ltd pursuant to the Underwriting Agreement. The Underwriter Options will be issued on
the same terms as the Entitlement Options: each Underwriter Option will have an exercise price of $0.02 and will expire on the
date which is 2 years and 6 months from the date of issue of the Entitlement Options.
The Underwriter Options will not be quoted on ASX.
Entitlement Options and Underwriter Options
The Entitlement Options and Underwriter Options (together, the Options) are being offered under this Prospectus and will be
issued on the same terms.
The Company will not apply for quotation of the Options on the ASX.
Instrument 2026/94
This Prospectus has been prepared, in part, to ensure that the relief provided under ASIC Corporations (Sale Offers That Do Not
Need Disclosure) Instrument 2026/94 (Instrument 2026/94) is available in respect of the Options. Instrument 2026/94 provides
relief from the on-sale provisions of section 707 of the Corporations Act and will relieve the need for any further disclosure to be
made prior to the on-sale of Shares issued following the exercise of Options, within 12 months of the date of issue of the Shares.
Shares issued on exercise of the Options will be able to be immediately traded on ASX (subject to the grant of quotation).
Target Market Determination
In accordance with the design and distribution obligations under the Corporations Act, the Company has determined the target
market for the offer of Options issued under this Prospectus. A ‘Target Market Determination’ (TMD) in respect of the offers of
Options under this Prospectus has been prepared by the Company and is available on the Company’s website:
https://cynata.com.
The TMD seeks to offer potential investors an understanding of the class of investors for which the offers of Options have been
designed, having regard to the objectives, financial situation and needs of the target market.
P a g e | 2
cytl0001_2100021_207.docx
The Company will only distribute this Prospectus to those investors who fall within the TMD.
By making an Application for Options under an Offer, you warrant that you have read and understood the TMD and that you fall
within the target market set out in the TMD.
Exposure period and cooling off rights
No exposure period applies to this Prospectus by operation of ASIC Corporations (Exposure Period) Instrument 2026/90.
Cooling off rights do not apply to an investment in New Shares or Options. You cannot withdraw your Application once it has been
accepted.
Obtaining a Prospectus and Entitlement and Acceptance Form
Applications for New Shares and Entitlement Options (together, New Securities) offered pursuant to this Prospectus in respect of
the Entitlement Offer can be submitted on an Entitlement and Acceptance Form. Eligible Shareholders will be able to access a
copy of this Prospectus and a personalised Entitlement and Acceptance Form via Automic’s website:
https://portal.automic.com.au/investor/home. The Prospectus will also be available on ASX’s website (www.asx.com.au).
Paper copies of this Prospectus and an Entitlement and Acceptance Form can be obtained free of charge during the Offer Period
by calling the Company’s share registry, Automic Pty Ltd (Share Registry) on 1300 288 664 (within Australia) or +61 (2) 9698
5414 (outside Australia), from 8.30am to 7.00pm (Melbourne time), Monday to Friday.
Electronic prospectus
This Prospectus is available and accompanies the Entitlement and Acceptance Form, which will be available via the Share
Registry’s website at https://portal.automic.com.au/investor/home. The Entitlement and Acceptance Form accompanying the
electronic version of this Prospectus must only be used within Australia, New Zealand and Singapore. An Entitlement and
Acceptance Form cannot be downloaded without also downloading this Prospectus. Electronic versions of this Prospectus should
be downloaded and read in their entirety. Applications for New Securities under the Entitlement Offer may only be made on the
Entitlement and Acceptance Form by following the instructions on your personalised Entitlement and Acceptance Form.
The Underwriter will provide an Application Form to each participant in the Shortfall Offer (which will be accompanied by a copy of
this Prospectus).
Investor warning
The Offers contained in this Prospectus do not take into account the investment objectives, financial position and particular needs
of individual investors. It is important that you read this Prospectus and the TMD carefully and in full before deciding to apply for
New Securities and Underwriter Options. In particular, you should consider the risk factors that could affect the financial
performance of the Company in light of your personal circumstances and seek professional advice from your accountant, tax
adviser, stockbroker, lawyer or other professional adviser before deciding to invest.
No representation other than in this Prospectus
No person is authorised to give information or to make any representation in connection with this Prospectus, which is not
contained in the Prospectus. Any information or representation not so contained may not be relied on as having been authorised
by the Company in connection with this Prospectus.
Except as required by law, and only to the extent so required, neither Cynata nor any other person warrants or guarantees the
future performance of the Company or any return on any investment made pursuant to this Prospectus, or on the exercise of the
Options issued under this Prospectus.
Risk factors
Potential investors should be aware that subscribing for the New Securities and Underwriter Options and exercising any Options
involves a number of risks. The key risk factors which investors should be aware of are set out in Section 8 of this Prospectus.
These risks, together with other general risks applicable to all investments in listed and unlisted securities, which are not
specifically referred to, may affect the value of the New Securities and Underwriter Options in the future.
Entitlement Offer for Australian, New Zealand and Singaporean residents only
The New Securities to be issued under this Prospectus in respect of the Entitlement Offer will only be offered to Eligible
Shareholders, being Shareholders with a registered address in Australia, New Zealand or Singapore at 7.00pm (Melbourne time)
on the Record Date. The distribution of this Prospectus in jurisdictions outside Australia and New Zealand may be restricted by
law. Seek advice on and observe any restrictions. This Prospectus is not an offer in any place where, or to any person to whom, it
would not be lawful to make the Offer. In particular, this Prospectus and the New Securities and Underwriter Options to be issued
under the Prospectus have not been, and will not be, registered under the US Securities Act of 1933 (as amended) and the New
Securities may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under
the US Securities Act and applicable US state securities laws.
You may only apply for New Shares in Australian dollars. You can contact the Share Registry on 1300 288 664 (within Australia)
or +61 (2) 9698 5414 (outside Australia) from 8.30am to 7.00pm (Melbourne time) Monday to Friday, if you are an Eligible
Shareholder but are unable to pay for New Shares in Australian dollars.
New Zealand
This document has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial
Markets Conduct Act 2013 (the “FMC Act”).
The New Shares and Options are not being offered to the public within New Zealand other than to existing shareholders of the
Company with registered addresses in New Zealand to whom the offer of these securities is being made in reliance on the
Financial Markets Conduct (Incidental Offers) Exemption Notice 2021.
P a g e | 3
cytl0001_2100021_207.docx
This document has been prepared in compliance with Australian law and has not been registered, filed with or approved by any
New Zealand regulatory authority under the FMC Act. This document is not a product disclosure statement under New Zealand
law and is not required to, and may not, contain all the information that a product disclosure statement under New Zealand law is
required to contain.
Other than in the Entitlement Offer, the New Shares and Options may only be offered or sold in New Zealand (or allotted with a
view to being offered for sale in New Zealand) to a person who:
• is an investment business within the meaning of clause 37 of Schedule 1 of the FMC Act;
• meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act;
• is large within the meaning of clause 39 of Schedule 1 of the FMC Act;
• is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act; or
• is an eligible investor within the meaning of clause 41 of Schedule 1 of the FMC Act.
Singapore
This document and any other materials relating to the New Securities have not been and will not be lodged or registered as a
prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this document and any other document relating to
the New Securities may not be issued, circulated or distributed, nor may the New Securities be offered or sold, or be made the
subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore except pursuant to and
in accordance with exemptions in Subdivision (4) Division 1, Part 13 of the Securities and Futures Act 2001 of Singapore (the
SFA) or another exemption under the SFA.
This document has been given to you on the basis that you are an existing holder of the Company’s Shares. If you are not such a
shareholder, please return this document immediately. You may not forward or circulate this document to any other person in
Singapore.
Any offer is not made to you with a view to the New Securities being subsequently offered for sale to any other party in Singapore.
On-sale restrictions in Singapore may be applicable to investors who acquire such securities. As such, investors are advised to
acquaint themselves with the SFA provisions relating to resale restrictions in Singapore and comply accordingly.
Financial information and forward looking statements
Section 7 sets out the financial information referred to in this Prospectus and the basis of preparation of that information. Any
discrepancies between totals and sums of components in tables contained in this Prospectus are due to rounding.
This Prospectus contains forward looking statements which are identified by words such as “may”, “could”, “believes”, “estimates”,
“expects”, “intends” and other similar words that involve risks and uncertainties. Any forward looking statements are subject to
various risk factors that could cause the Company’s actual results to differ materially from the results expressed or anticipated in
these statements. Forward looking statements should be read in conjunction with the risk factors set out in Section 8, and other
information in this Prospectus.
Defined words and expressions
Some words and expressions used in this Prospectus have defined meanings. These words and expressions are defined
throughout the Prospectus or in the Glossary in Section 11.
A reference to $ or cents in this Prospectus is a reference to Australian currency (unless otherwise stated). A reference to time in
this Prospectus is a reference to Melbourne, Australia time.
Photographs and diagrams
Any photographs used in this Prospectus without descriptions are only for illustration. Any diagrams used in this Prospectus may
not be drawn to scale.
Privacy
If you apply for New Securities or Underwriter Options, you will provide personal information to the Company and the Share
Registry. The Company and the Share Registry collect, hold and use your personal information in order to assess your
Application, service your needs as a holder of the Shares and Options, provide facilities and services that you request and carry
out appropriate administration. Company and tax laws require some of the information to be collected. If you do not provide the
information requested, your Application may not be able to be processed efficiently, or at all.
Each of the Company and the Share Registry may disclose your personal information for purposes related to your Share and
Option holding to each other and to their respective agents and services providers including those listed below or as otherwise
authorised under the Privacy Act 1988 (Cth) (Privacy Act):
• in the case of the Company, to the Share Registry for ongoing administration of the Share and Option registers; and
• in the case of the Company and the Share Registry, to printers and mailing houses for the purposes of preparation and
distribution of security holder information and for handling of mail.
Under the Privacy Act, you may request access to your personal information held by (or on behalf of) the Company or the Share
Registry. You can request access to your personal information by contacting the Company’s Share Registry at
https://www.automicgroup.com.au/privacy-policy/ or by phone on 1300 288 664 (within Australia) or +61 (2) 9698 5414 (outside
Australia).
P a g e | 4
cytl0001_2100021_207.docx
CONTENTS
Section Page
Important Notice 1
Contents 4
Chairman’s Letter 5
1. Key Dates 7
2. Summary of the Offers 8
3. Investment Overview 9
4. Details of the Offers 13
5. Applying under the Offers 16
6. Purpose and Effect of the Offers 24
7. Financial Information 27
8. Risk Factors 29
9. Rights and Liabilities Attaching to Securities 33
10. Additional Information 38
11. Glossary 46
12. Corporate Directory 49
P a g e | 5
cytl0001_2100021_207.docx
CHAIRMAN’S LETTER
Dear Shareholder
On behalf of the Directors of Cynata, I invite you to participate in the Entitlement Offer.
Company update
The Company’s core asset is currently the Cymerus™ platform, which offers a genuinely differentiated
approach to manufacturing mesenchymal stromal cells (MSCs) at commercial scale from a single,
consistent cell source.
Subsequent to the announcement of the Phase 2 acute graft versus host disease (aGvHD) Trial
Preliminary Evaluation Results (17 June 2026) and CYP-004 Osteoarthritis Trial Results (19 June 2026),
the Board is now focused on evaluating the future development pathways available for this technology,
and the broader strategic options open to the Company. This includes seeking opportunities to realise
value from the Cymerus™ technology and obtain rights to new assets.
The Company also announced Board and management changes and expenditure reductions on 6 July
2026, which included the transition of Dr Kilian Kelly from Managing Director to Non-Executive Director.
Overview of Entitlement Offer
The Company is raising gross proceeds of approximately $913,000 before costs, by way of a pro rata,
non-accelerated, renounceable entitlement offer of 3 New Shares for every 8 Shares held by Eligible
Shareholders at 7.00pm (Melbourne time) on Tuesday, 13 October 2026 (Record Date), at the Offer
Price of $0.01 per New Share (Entitlement Offer).
The Offer Price of $0.01 per New Share represents a discount of 9.1% to the closing price of Shares on
ASX on 7 October 2026 (of $0.011 per Share).
Eligible Shareholders will not be able to apply for New Shares in excess of their Entitlement under the
Entitlement Offer.
The Entitlement Offer is being lead managed and fully underwritten by the Underwriter, Caravel Securities
Pty Ltd.
In addition, for every three New Shares that are issued pursuant to the Entitlement Offer, participants in
the Entitlement Offer will be offered one new free attaching option for nil cash consideration.
Each option issued under the Entitlement Offer will entitle the holder to subscribe for one Share and will
have an exercise price of $0.02 and will expire on the date that is 2 years and 6 months after the date of
issue of the options (Entitlement Options).
The Entitlement Options will not be quoted on ASX.
The Entitlement Offer is renounceable, meaning that Eligible Shareholders are able to renounce their
rights and seek to trade those rights on ASX during the Entitlement Trading Period commencing on
Monday, 12 October 2026 (on a deferred settlement basis) and ending on Tuesday, 20 October 2026.
In addition to the Entitlement Offer, this Prospectus also includes the Underwriter Option Offer and the
Shortfall Offer.
Use of proceeds of Entitlement Offer
The proceeds from the Entitlement Offer will be used to:
• pay for professional adviser, Director and consultant fees in furtherance of the Company’s strategic
objectives; and
• pay for the costs of the Offers and for working capital purposes.
P a g e | 6
cytl0001_2100021_207.docx
Further details are provided in Section 4.5.
Share Sale Facility
The Company is also intending to undertake an unmarketable parcel Share Sale Facility. Refer to its ASX
announcements (available at www.asx.com.au) for further details.
Action you should take
The Entitlement Offer is currently scheduled to close at 5.00pm (Melbourne time) on Tuesday, 27 October
2026. If you wish to subscribe for New Securities under the Entitlement Offer, you must ensure that your
Application and payment are received by this time in accordance with the instructions set out in Section
5.
Prospectus
This Prospectus contains important information regarding the Offers, and I encourage you to read it
carefully before making any investment decision, having particular regard to the ‘Risk Factors’ outlined in
Section 8 of this Prospectus.
If you have any questions, you should consult your financial or other professional adviser.
On behalf of the Board of Directors, I thank you for your support of Cynata.
Yours sincerely,
Dr Geoffrey Brooke
Chairman
Cynata Therapeutics Limited
P a g e | 7
cytl0001_2100021_207.docx
1 KEY DATES
The key dates in respect of the Offers are as follows.
Event Date (2026)
Prospectus lodged with ASIC and ASX and Appendix 3B lodged
with ASX
Thursday, 8 October
Ex-date for Entitlement Offer
Entitlement trading commences on a deferred settlement basis
Monday, 12 October
Record Date for eligibility to participate in the Entitlement Offer Tuesday, 13 October
Offer Opening Date
Prospectus and Entitlement and Acceptance Form available to
Eligible Shareholders
Underwriter Option Offer opens
Friday, 16 October
Entitlement trading ends at ASX market close Tuesday, 20 October
Offer Closing Date
Entitlement Offer and Underwriter Option Offer close
Tuesday, 27 October
Announcement of results of the Entitlement Offer Friday, 30 October
Issue of New Shares and Entitlement Options under the
Entitlement Offer and Underwriter Options under Underwriter
Option Offer
Tuesday, 3 November
Trading of New Shares issued under the Entitlement Offer Wednesday, 4 November
Despatch of holding statements for New Shares and Options Wednesday, 4 November
Cynata reserves the right to vary these times and dates, by agreement with the Underwriter. All times
are Melbourne times.
P a g e | 8
cytl0001_2100021_207.docx
2 SUMMARY OF THE OFFERS
Entitlement Offer
Entitlement Offer ratio 3 New Shares for every 8 Shares held by
Eligible Shareholders on the Record Date
(Tuesday, 13 October 2026) together with one
Entitlement Option for every 3 New Shares
issued
Offer Price $0.01 per New Share
Number of New Shares offered under the
Entitlement Offer
91,295,388
Number of Entitlement Options offered under the
Entitlement Offer
30,431,796
Proceeds of the Entitlement Offer (before costs) Approximately $913,000
Underwriter Option Offer
Number of Underwriter Options offered under the
Underwriter Option Offer
18,000,000
Issued Capital on completion of the Offers
Shares on issue as at the Prospectus Date 243,454,369
Shares on issue on completion of the Offers 334,749,757
Options on issue as at the Prospectus Date 7,993,888
Options on issue on completion of the Offers 56,425,684
Final numbers will vary slightly as a result of rounding.
P a g e | 9
cytl0001_2100021_207.docx
3 INVESTMENT OVERVIEW
This information is selective only.
You should read this Section in conjunction with the details of the Offers set out in Section 4 of
this Prospectus and the remainder of the Prospectus, together with the Company’s ASX releases.
Topic Summary Further
Information
What are the
Company’s current
business
objectives?
The Company’s core asset is currently the Cymerus™
platform, which offers a genuinely differentiated approach to
manufacturing mesenchymal stromal cells (MSCs) at
commercial scale from a single, consistent cell source.
Subsequent to the announcement of the Phase 2 aGvHD
Trial Preliminary Evaluation Results (17 June 2026) and
CYP-004 Osteoarthritis Trial Results (19 June 2026), the
Board is now focused on evaluating the future development
pathways available for this technology, and the broader
strategic options open to the Company. This includes
seeking opportunities to realise value from the Cymerus™
technology and obtain rights to new assets.
Chairman’s
Letter
Entitlement Offer The Entitlement Offer is being made as a pro rata, non-
accelerated, renounceable entitlement offer of 3 New
Shares for every 8 Shares held by Eligible Shareholders on
the Record Date at the Offer Price of $0.01 per New Share,
together with one free attaching Entitlement Option for
every 3 New Shares issued, to raise approximately
$913,000.
Each Entitlement Option will be issued (for no cash
consideration) with an exercise price of $0.02 and is
exercisable on or before the date that is two years and six
months after the date of issue of the Entitlement Options.
Any fractional entitlements to New Shares or Options will be
rounded up to the nearest whole number.
Sections 4.1
and 4.2
Underwritten
Entitlement Offer
The Entitlement Offer is fully underwritten by the
Underwriter, Caravel Securities Pty Ltd, subject to the terms
of the Underwriting Agreement.
Section 10.3
Purpose of the
Entitlement Offer
The proceeds from the Entitlement Offer will be used to:
• pay for professional adviser, Director and consultant
fees in furtherance of the Company’s strategic
objectives; and
• pay for the costs of the Offers and for working capital
purposes.
Section 4.5
Eligible
Shareholders for
Entitlement Offer
Eligible Shareholders are eligible to participate in the
Entitlement Offer, being Shareholders who:
• are a registered holder of Shares at 7.00pm (Melbourne
time) on the Record Date, being Tuesday, 13 October
2026;
• have a registered address in Australia, New Zealand or
Singapore; and
• are not in the United States and are not acting for the
account or benefit of a person in the United States.
Sections 5.1
and 5.18
Offer Price The Offer Price for the New Shares is $0.01 per New Share. Sections 4.1,
4.2 and 4.3
P a g e | 10
cytl0001_2100021_207.docx
Topic Summary Further
Information
The Options are offered to participants in the Entitlement
Offer for nil cash consideration on the basis of 1 Option for
every 3 New Shares subscribed for under the Entitlement
Offer.
The Underwriter Options are being offered for nil cash
consideration.
Shortfall Offer Any Entitlements not taken up under the Entitlement Offer
will become Shortfall Securities and be offered pursuant to
the Shortfall Offer (a separate offer under this Prospectus).
The New Shares offered under the Shortfall Offer will be
issued at the Offer Price and on the same terms and
conditions as the New Shares offered under the Entitlement
Offer. Applicants for New Shares will also receive
Entitlement Options on the same basis as participants in the
Entitlement Offer.
The allocation of any Shortfall Securities will be determined
by the Underwriter, subject to the terms of the Underwriting
Agreement, and may include allocations to Institutional
Investors who have committed to sub-underwrite the offer of
New Securities under the Entitlement Offer.
The Company and the Underwriter may invite Institutional
Investors to participate in the Shortfall Offer.
Section 4.4
Underwriter
Options
In consideration for services to be performed by the
Underwriter in connection with the Entitlement Offer, the
Company has agreed to offer the Underwriter (or
nominee(s)) 18,000,000 Underwriter Options, to be issued
on completion of the Entitlement Offer.
The Underwriter Options are being offered to the
Underwriter (or nominee(s)) on the same terms as the
Entitlement Options to be issued under the Entitlement
Offer.
Section 4.3
Participation and
key risks
The Shares and Options offered under this Prospectus
should be considered highly speculative.
Cynata recommends you seek independent financial advice
from your stockbroker, accountant or other professional
adviser.
Before making any application for New Securities, Eligible
Shareholders should consider the specific and general risk
factors facing Cynata’s business and the risks of investing
in New Shares and Options.
Some of those key risks include:
• risks associated with the Company’s limited financial
resources and funding requirements;
• business development and new asset acquisition risks;
• clinical development risks;
• commercialisation and strategic transaction risks;
• intellectual property and in-licensed technology risks;
and
• risks associated with the Company’s streamlined
operating model and its reliance on e
Share your feedback
Discover